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Introduction
Hepatitis C virus (HCV) is an important public health 
problem worldwide that causes acute and chronic liver 
diseases like cancer. Approximately 80% of subjects with 
acute hepatitis C progress into a chronic disease. Chronic 
hepatitis C virus (CHC) infection is an important cause 
for developing (10-20%) cirrhosis and hepatocellular 
carcinoma (HCC) that often results in liver failure and 
thus in liver transplantation (Keyvani et al., 2012). HCC 
is the seventh most common cancer worldwide and the 
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Abstract
 Background: A recent genome-wide association study (GWAS) on patients with chronic hepatitis C (CHC) 
treated with peginterferon and ribavirin (pegIFN-α/RBV) identified a single nucleotide polymorphism (SNP) 
on chromosome 19 (rs12979860) which was strongly associated with a sustained virological response (SVR). The 
aim of this study was twofold: to study the relationship between IL28B rs12979860 and sustained virological 
response (SVR) to pegIFN-α/RVB therapy among CHC patients and to detect the rs12979860 polymorphism by 
high resolution melting curve (HRM) assay as a simple, fast, sensitive, and inexpensive method. Materials and 
Methods: The study examined outcomes in 100 patients with chronic hepatitis C in 2 provinces of Iran from 
December 2011 to June 2013. Two methods were applied to detect IL28B polymorphisms: PCR-sequencing as a 
gold standard method and HRM as a simple, fast, sensitive, and inexpensive method. Results: The frequencies of 
IL28B rs12979860 CC, CT, and TT alleles in chronic hepatitis C genotype 1a patients were 10% (10/100), 35% 
(35/100), and 6% (6/100) and in genotype 3a were 13% (13/100), 31% (31/100), and 5% (5/100), respectively. 
In genotype 3a infected patients, rs12979860 (CC and CT alleles) and in genotype 1a infected patients (CC 
allele) were significantly associated with a sustained virological response (SVR). The SVR rates for CC, CT and 
TT (IL28B rs12979860) were 18%, 34% and 4%, respectively. Multiple logistic regression analysis identified 
two independent factors that were significantly associated with SVR: IL-28B genotype (rs 12979860 CC vs TT 
and CT; odds ratio [ORs], 7.86 and 4.084, respectively), and HCV subtype 1a (OR, 7.46). In the present study, 
an association between SVR rates and IL28B polymorphisms was observed. Conclusions: The HRM assay 
described herein is rapid, inexpensive, sensitive and accurate for detecting rs12979860 alleles in CHC patients. 
This method can be readily adopted by any molecular diagnostic laboratory with HRM capability and will be 
clinically beneficial in predicting treatment response in HCV genotype 1 and 3 infected patients. In addition, it 
was demonstrated that CC and CT alleles in HCV-3a and the CC allele in HCV-1a were significantly associated 
with response to pegIFN-α/RBV treatment. The present results may help identify subjects for whom the therapy 
might be successful. 
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third most common cause of cancer mortality (Yang and 
Roberts., 2010). HCC usually expands in patients infected 
with chronic hepatitis B (HBV) or chronic hepatitis 
C (CHC). HBV vaccination programs among general 
population in high risk areas and using antiviral treatment 
in chronic hepatitis C and B, could be prevented liver 
cancer (Su et al., 2013). In Iran, incidence of hepatocellular 
carcinoma is low because most cases are due to HBV 
and this infection was less common (Pourhoseingholi et 
al., 2010). 
Although successful execution of direct-acting 
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antiviral therapy was recently demonstrated in Western 
countries, combination pegylated interferon-alpha 
(pegIFN-α) plus ribavirin (RBV) (pegIFN-α/RVB) is 
still the most effective treatment for patients with CHC in 
central Asia (Beinhardt et al., 2013; Ghany et al., 2009). 
Standard of care (SOC) for treatment of CHC infection 
is pegIFN-α/RVB, that leads to sustained virological 
response (SVR) in about 40%-60% of subjects with 
CHC genotype 1 (HCV-1) and 80% or more in those with 
genotypes 2 and 3 of this infection (Tsubota et al., 2011). 
Higher SVR rates have been obtained in subjects infected 
with other HCV genotypes (Ge et al., 2009; Antaki et 
al., 2010; Tsubota et al., 2011; European Association 
for the Study of the Liver., 2014) and middle SVR 
rates have been obtained in those with HCV genotype 4 
(Antaki et al., 2010). Interestingly, Iranian patients with 
CHC respond better to SOC treatment (Alavian et al., 
2010). Of the various host (age, sex, body mass index, 
race, usage immunosuppressive drugs, host genetic, 
sex, stage of fibrosis, coinfection with other hepatitis 
viruses and human immunodeficiency virus) and viral 
factors (HCV genotype, HCV viral load) associated with 
the effectiveness of pegIFN-α/RVB therapy (European 
Association for the Study of the Liver., 2014). 
A recent genome-wide association study (GWAS) on 
patients with CHC treated with pegIFN-α/RVB identified a 
single nucleotide polymorphism (SNP) on chromosome 19 
(rs12979860 and rs8099917) that was strongly associated 
with sustained virological response (SVR). The CC alleles 
(rs12979860) and TT alleles (rs8099917) were associated 
with SVR compared with the TT (rs12979860) and GG 
(rs8099917) alleles which increasing the possibility that 
the C allele may favour spontaneous clearance of HCV 
(Ge et al., 2009). There are different opinions for clinical 
determination of IL28B testing; but, it seems that it can 
help in decision-making with regard to treatment (Grebely 
et al., 2010). IL28B alleles are the robust pretreatment 
prognosticator of SVR to pegIFN-α/RVB and protease 
inhibitor triple therapy in patients with HCV-1 infection. 
Testing may be considered when the patient or provider 
wants additional information on the probability of 
treatment response or the probable duration of the needed 
treatment (Class 2a, Level B) (Ghany et al., 2011).
Several methods, such as direct DNA sequencing, 
real-time PCR, amplification refractory mutation system 
polymerase chain reaction (ARMS-PCR), polymerase 
chain reaction-restriction fragment length polymorphism 
(PCR-RFLP) and allele-specific PCR can be used for 
genotyping SNPs, such as IL28B alleles (Chen et al., 
2003). 
The aim of this study was twofold: to study the 
relationship between IL28B rs12979860 and SVR to 
pegIFN-α/RVB therapy among CHC patients and to 
detecting rs12979860 polymorphism by High Resolution 
Melting Curve (HRM) as a simple, fast, sensitive, and 
inexpensive method.
Materials and Methods
Patients
 One hundred (n=100) patients with chronic hepatitis C 
in 2 provinces of Iran (Digestive Disease Research Center 
of Tehran and Virology Laboratory of the Besat Specialist 
Clinic of Kerman, IRAN from) from December 2011 to 
June 2013 enrolled this study. 
 The exclusion criteria included having other hepatitis 
virus (hepatitis B and D viruses), using immunosuppressive 
drugs (organ transplantation), diabetes mellitus, coexistent 
autoimmune liver diseases and having any of the various 
diseases that suppress the immune system (human 
immunodeficiency virus).
Treatment of patients
 One hundred patients were treated with 180 milligram 
per week (mg/week) of Pegylated interferon alfa-2a 
(Peg-IFNα-2a) and 1000-1200 milligram per day (mg/
day) of ribavirin (RBV). The patients with chronic HCV 
genotypes 1a and 3 were treated for 48 and 24 weeks, 
respectively (Alavian et al., 2010). To determine the end 
of the treatment, the viral load (HCV RNA) in blood was 
measured at the end of the treatment and 6 months later. 
The absence of detectable RNA of HCV in blood for at 
least 24 weeks after discontinuing treatment was defined 
as a Sustained Virologic Response (SVR) (Figure 1). 
Sample collection
 About 8 mL blood samples from HCV patients were 
collected in Ethylenediaminetetraacetic acid (EDTA) 
tubes. Plasma was separated and aliquoted. Then, it 
was stored at -80ºC until analysis. Peripheral blood 
mononuclear cells (PBMCs) were isolated using Ficoll 
(Ficoll-Paque PLUS, GE Healthcare) and stored at -20°C.
RNA and DNA extraction 
 HCV RNA was extracted from 200 μl plasma samples 
using a high pure RNA isolation kit (Roche, Germany). 
Purified RNA can be stored at -80°C for later analysis.
IL28B DNA was extracted from 200μl PBMC samples 
using a high pure PCR template preparation kit (Roche, 
Germany). Purified DNA can be used directly or 
stored at +2 to +8°C for later analysis. DNA and 
RNA concentrations were detected by calculating the 
absorbance ratio OD260nm/280nm using Thermo 
Scientific™ NanoDrop-2000 model (Thermo Scientific, 
Wilmington, DE).
Virologic testing
 HCV genotyping and HCV viral loading from plasma 
samples were carried out using the AmpliSens® HCV-
1/2/3-FEP PCR kit and AmpliSens® HCV-Monitor-FRT 
Real-Time PCR kit (InterLabService Ltd., Moscow) 
according to the manufacturer’s instructions, respectively.
Laboratory procedures 
 Liver enzyme function tests were carried out for all 
the patients. Alanine Aminotransferase (ALT), Aspartate 
Aminotransferase (AST), and alkaline phosphatase (ALP) 
were measured on the Selectra E Clinical Chemistry 
analyzer (Vital Scientific, The Netherlands).
High resolution melting curve (HRM)
 IL28B rs12979860C>T alleles were diagnosed from 
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PBMC samples using HRM assay. Primer sequences 
were used for amplifications as follows: forward primer: 
5’-CCTGGACGTGGATGGGTA-3’ and reverse primer: 
5’-GCGCGGAGTGCAATTCAA-3’. 
 The real-time PCR (20 μl) was composed of 10 μl 
of 2×AccuMelt HRM SuperMix (Quanta BioSciences, 
Inc, USA), forward and reverse primers (0.25 μl of each 
primer was used), nuclease-free water (4.5 μl), and DNA 
extracted from PBMCs (5 μl). The reactions were set up 
in triplicate in a 96-well PCR plate and processed on a 
CFX96 Touch™ Real-Time PCR Detection System (Bio-
Rad Laboratories, Inc). CFX Manager Software Version 
3.0 (Bio-Rad Laboratories, Inc) was applied to set up the 
sample arrangement on the PCR plate, to define PCR 
conditions, to monitor the amplification in real time, to 
view melting curves, and to calculate DNA concentrations 
and other PCR parameters.
 The amplification reaction mixture consisted of 30 
ng of genomic DNA; the cycling parameters of PCR 
were as follows: 95°C for 5 min followed by 45 cycles 
of 95°C for 10s, 60°C for 30 s, and 60°C for 30 s. Then, 
high-resolution melt curves analysis was carried out by 
fluorescence acquisition during a temperature increase 
from 60°C to 95°C, using increments of 0.1°C with 
holding steps of 10 s (Figure 2).
PCR Sequencing 
 To confirm the HRM method, the HRM genotyping 
results of rs12979860 should be 100% compatible with 
the DNA sequencing consequences. The primers for PCR 
and sequencing reactions were as follows: forward primer: 
5’-CTCTGCACAGTCTGGGATTCCT-3’ and reverse 
primer: 5’-CTGAGGGACCGCTACGTAAGTC-3’. 
The amplification reaction mixture consisted of 50ng of 
genomic DNA, forwards and reverse primers (0.15 µM of 
each), different deoxynucleotides (0.2 mM of each), Ex 
Taq DNA Polymerase (1.5U) (Takara, Korea Biomedical, 
Inc), and PCR buffer (10X) containing 1.5 mM MgCl2. 
First, the PCR was performed by denaturing the samples 
(for 10 min at 95°C); then, 35 cycles including 95°C for 
45 s, 66°C for 45 s, 72°C for 45s, and a final extension 
at 72°C for 10 min were followed. Electrophoresis of 
the PCR products were carried out on the agarose gels 
(1%). PCR products (390 bp) were purified by High Pure 
PCR Product Purification Kit (Roche, Germany) then, 
three IL28B 12979860 genotypes (TT, CT and CC) were 
analyzed by direct sequencing (Figure 3).
Statistical analysis
 All the calculations were performed using SPSS 
version 21 software (SPSS, Inc., Chicago, IL). Predictors 
for SVR were evaluated by multivariate logistic regression 
analysis. Multivariate analysis included all significant 
parameters from univariate analysis as well as the 
parameters that were available from all patients. Analysis 
of continuous variables was performed using independent-
samples t-test and Kruskal-Wallis test. χ2 and Fisher’s 
exact tests were used for comparing frequency data and 
evaluating the relationships between groups. Differences 
with the p-value of >0.05 were considered statistically 
significant.
Ethics statement
 The current study was approved by Ethical Committee 
of School of Public Health, Tehran University of Medical 
Sciences. An informed consent was also directly obtained 
from each patient.
Results 
Patient characteristics
One hundred patients (n=100) with chronic HCV 
infection were followed up in this study. There were 51 
patients (n=51) with HCV genotype 1a and 49 patients 
(n=49) with HCV genotype 3a infection. Mean age of 
the patients (84 males and 16 females) was 52.2±4.6 
	  
Figure 2. High Resolution Melting Curve (HRM) 
Analysis for Detection of IL28B rs12979860 Genotype
Figure 1. Flow Diagram of the 100 Iranian Patients 
with Chronic Hepatitis C 
	  
Figure 3. PCR-Sequencing Chromatograms for IL28B 
rs12979860 Genotype. (A) CC genotype. (B) CT genotype: 
double peaks at SNP position. (C) TT genotype
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(ranging from 41 to 61 years old). Pretreatment clinical 
and virological characterizations including alanine 
transaminase (ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (ALKP), HCV genotype, and HCV 
viral load are showed in Table 1.There were no significant 
differences between HCV genotypes and age, ALT, AST, 
and ALKP levels, whiles they were significantly different 
from HCV viral load (p=0.018). 
The sustained virological response (SVR) rate in the 
patients with HCV genotype 1a and 3a infection was 18 
(35.3%) and 38 (77.55%), respectively. SVR rate in HCV 
genotype 1a was significantly less than of the patients with 
HCV genotype 3a (p=<0.001) (Figure 1). Among the HCV 
genotype 1a and HCV genotype 3a groups, 33 (64.7%) 
and 11 (22.45%) patients were non-responders (Non-
SVR). No significant differences were found between the 
HCV treatment response (SVR) and age, sex, baseline 
liver enzymes levels (ALT, AST, and ALKP), whereas a 
significant relationship between SVR rate and HCV viral 
load was shown (p=0.041) (Table 2).
Prevalence of rs12979860 genotype according to HCV 
genotypes
In the current study, prevalence of rs12979860 
genotypes CC, CT, and TT in HCV genotype 1a was 
10 (10%), 35 (35%), and 6 (6%), respectively and in 
HCV genotype 3a, it was 13 (13%), 31 (31%), and 5 
(5%), respectively (Table 3). No statistically significant 
difference was seen between rs12979860 genotype and 
HCV genotype (p=0.710).
Relationship between rs12979860 genotypes with 
Laboratory parameters
Baseline serum ALT, AST, and ALKP levels in 
the patients with CC genotype of rs12979860 were 
248.8±245.9, 248.8±245.9, and 586.4±360.7, respectively. 
Among the patients with non-CC genotype, they were 
256.6±215.3, 246.3±195.1, and 607.5±418.8, respectively. 
This difference was not statistically significant (p=0.661 
vs 0.689) (Table 3).
Baseline viral load in the patients with CC genotype 
was less than the patients with non-CC genotype of 
rs12979860; but, no significant difference was found in the 
baseline viral load between the patients with CC genotype 
and non-CC genotype of rs12979860 (3.3×106±1.7×106 
vs 4.6×106±2.5×106 and 4.5×106±2.4×106, respectively, 
p=0.127). 
Sustained Virological Response Rates According to 
rs12979860 Genotypes
Out of 100 patients of CHC subjects, 51 patients 
(51%) were infected with HCV genotype 1a and 49 
patients (49%) with genotype 3a. Among 51 patients with 
HCV genotype 1a infection, 18 (35.3%) subjects and 49 
patients with HCV genotype 3a infection, 38 (77.5%) 
subjects were treated, respectively and evaluable on the 
achievement of SVR. For 18 patients with HCV genotype 
1a infection, frequencies of rs12979860 CC, CT, and TT 
genotypes in SVR subjects were 6, 11, and 1, respectively, 
while in non-SVR subjects, the frequencies were 4, 24, 
and 5, respectively. CC genotype of rs12979860 was 
significantly associated with SVR compared to non-CC 
genotype (p=0.032).
For 38 patients with HCV genotype 3a infection, 
frequencies of rs12979860 CC, CT, and TT genotypes in 
SVR subjects were 12, 23, and 3, respectively. In contrast, 
in non-SVR subjects, the frequencies were 1, 8, and 2, 
respectively. Two (CC and CT) genotypes of rs12979860 
Table 2. Relationship between Baseline Demographic, Clinical, and Virological Characteristics with Sustained 
Virological Responders
Patients Features SVR Non-SVR Total p-value
Number of patients (%) 56 44 100 -
Age (years) 52.3±4.4 52.2±5.0 52.2±4.6 0.966
Gender (male/female) 48/8 36/8 84/16 0.784
HCV genotype     
    1a 18 (35.3%) 33 (64.7%) 51 (100%) <0.001a
    3a 38 (77.5%) 11 (22.5%) 49 (100%) 
HCV viral load (IU/ml) 3.8×106±2.2×106 4.9×106±2.5×106 4.3×106±2.3×106 0.041a
Baseline ALT level (IU/L) 243.9±248.2 260.2±205.2 252.1±226.7 0.236
Baseline AST level (IU/L) 223.7±197.8 260.2±199.0 241.9±198.4 0.125
Baseline ALK level (IU/L) 602.5±402.0 724.8±490.9 663.6±446.4 0.27
*SVR, sustained virologic response; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALKP, alkaline phosphatase. aStatistically Significant
Table 3. Relationship between Baseline Demographic, Clinical, Virological Characteristics and Sustained 
Virological Responders with rs12979860 IL28B polymorphisms
IL28B  rs12979860   
Variable CC CT TT p-value
HCV genotype (1a/3a) 10./13 35/31 6./5 0.71
Baseline viral load (IU/ml) 3.3×106±1.7×106 4.6×106±2.5×106 4.5×106±2.4×106 0.127
AST (IU/L) 243.4±240.1 253.0±183.3 239.7±206.9 0.661
ALT (IU/L) 248.8±245.9 262.2±217.3 251.1±213.3 0.689
ALKP (IU/L) 586.4±360.7 558.7±481.6 656.3±356.0 0.569
SVR 18 34 4 0.032a
Non-SVR 5 32 7 0.032a
*SVR, sustained virologic response; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALKP, alkaline phosphatase; aStatistically Significant
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were significantly associated with SVR (p=0.032).
Multiple logistic regression analysis identified two 
independent factors that were significantly associated 
with SVR: IL-28B genotype (rs 12979860 CC vs TT and 
CT; ORs, 7.86 and 4.084, respectively), and HCV subtype 
1a (OR, 7.46) (multivariate regression data not shown). 
Discussion
Many factors are important for the prediction of SVR 
in the patients with CHC before the initiation of antiviral 
therapy. These factors can assist physicians in decision-
making on whether to start antiviral therapy or not and also 
motivate patients that might have high odds for virological 
response. Previous studies have shown that HCV genotype, 
baseline viral load, age, gender, body mass index (BMI), 
stage of disease, race, alanine aminotransferase (ALT) 
level, and host genetic polymorphisms of several genes 
(human leukocyte antigen, chemokines, interleukins and 
IFN-stimulated genes) are associated with SVR (; Asselah 
et al., 2007; Wohnsland et al., 2007; Kau et al., 2008; Dai 
et al., 2009).
The recently published genome-wide association 
studies (GWAS) have provided insight into host genetic 
factors that are predictive of HCV disease progression 
and treatment outcome. Although several SNPs have an 
association with SVR and spontaneous HCV clearance, 
rs12979860 (CC genotype) and rs8099917 (TT genotype) 
have been identified by multiple groups with different 
patient cohorts (Melis et al., 2011).
There are different opinions for the clinical 
determination of IL28B testing; but, it seems that it can 
help in decision-making with regard to treatment (Grebely 
et al., 2010). IL28B alleles are the robust pretreatment 
prognosticator of SVR to pegIFN-α/RVB and protease 
inhibitor triple therapy in patients with HCV-1 infection. 
Testing may be considered when the patient or provider 
demands additional information on the probability of 
treatment response or the probable duration of the needed 
treatment (Class 2a, Level B) (Ghany et al., 2011).
The aim of this study was twofold: to study the 
relationship between IL28B rs12979860 and the sustained 
virological response to pegIFN-α/RBV therapy among 
CHC patients and determine rs12979860 polymorphism 
by HRM as a simple, fast, sensitive, inexpensive, sensitive 
and specific method. 
Recently, several studies describing assays for 
IL28B detecting have been published (Falleti et al., 
2011; Moghaddam et al., 2011). These were sequencing, 
also several non-sequencing assays such as restriction 
fragment length polymorphism (RFLP), TaqMan PCR, 
amplification refractory mutation system polymerase 
chain reaction (ARMS-PCR) and allele-specific PCR. 
Most of them are expensive, time-consuming and they 
need specific probes and instruments.
We have developed a reliable, fast, simple, inexpensive, 
sensitive and specific HRM method for genotyping of 
IL28B rs12979860 SNPs that is more cost-effective than 
sequencing. The HRM genotyping results (to confirm the 
HRM method) showed 100% concordant with the PCR-
sequencing results.
Poon et al have recently reported, this method can be 
readily adopted by any molecular diagnostic laboratory 
with HRM capability and will be clinically beneficial in 
predicting treatment response in HCV genotype 1 infected 
patients, also this method was sensitive and cost-effective 
(Poon et al., 2012). 
Out of 100 Iranian patients with chronic HCV, subtype 
1a was the most common subtype (51%) followed by 
subtype 3a (49%). The distribution of HCV genotype in 
the present study was very similar to other Iranian studies 
(Zali et al., 2000; Samimi-Rad et al., 2004; Keyvani et al., 
2007) but is different from observations in other Middle 
Eastern countries. As an example the overcoming HCV 
genotype was 1b in Turkey (Altuglu et al., 2008), 3a in 
Pakistan (Sajid et al., 2014) and 1b in Russia (Viazov et 
al., 1997). It is likely which differences in the race, routes 
of transmission, and different socioeconomic factors might 
describe this variation.
Liver enzymes (ALT, AST, and ALKP) are the key 
clinical appraisement for liver function, immune activation 
in HCV patients and SVR; but, the current study revealed 
no significant difference between liver enzymes levels, 
HCV genotype, IL28B rs12979860 polymorphism and 
SVR (Table 1, 3). Logistic regression analysis in the 
current study also demonstrated that pretreatment ALT, 
AST, and ALKP levels were not predictors of SVR in 
HCV patients. However, these results were consistent 
with the previous studies in that no associations were 
observed between these enzymes and IL28B rs12979860 
polymorphism and SVR rates (Akkarathamrongsin et al., 
2014; Eslam et al., 2014); in contrast, the results of the 
present study were consistent with a number of reports 
(Shi et al., 2012).
Liver enzymes levels were very important parameters 
for host factors that should be monitored carefully during 
Table 1. Characterization, Clinical, and Virological Properties of Iranian Patients with CHC before Anti-Viral 
Therapy with PEG-IFN2a/Ribavirin
Variable Patients 
HCV genotype 1a 3a Total p-value
No. (%) 51(51%) 49(49%) 100 (100%) 
Agea 52.8±4.7 51.7±4.6 52.2±4.6 0.259
  Laboratory Parameters  
AST (IU/L)a 261.3±203.8 217.3±191.6 239.3±197.7 0.31
ALT (IU/L)a 274.0±230.1 227.2±228.3 250.6±229.2 0.269
ALKP (IU/L)a 692.3±487.7 618.7±397.6 655.5±442.6 0.411
HCV Viral Load (IU/ml)a 4.9×106±2.5×106 3.7×106±2.2×106 4.3×106±2.4×106 0.018
*ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALKP, alkaline phosphatase; aContinuous parameters are presented as mean±standard deviation
Abolfazl Fateh et al
Asian Pacific Journal of Cancer Prevention, Vol 16, 20151878
0
25.0
50.0
75.0
100.0
N
ew
ly
 d
ia
gn
os
ed
 w
ith
ou
t 
tr
ea
tm
en
t 
N
ew
ly
 d
ia
gn
os
ed
 w
ith
 t
re
at
m
en
t 
Pe
rs
is
te
nc
e 
or
 r
ec
ur
re
nc
e
Re
m
is
si
on
N
on
e
Ch
em
ot
he
ra
py
Ra
di
ot
he
ra
py
Co
nc
ur
re
nt
 c
he
m
or
ad
ia
tio
n
10.3
0
12.8
30.025.0
20.310.16.3
51.7
75.0
51.1
30.031.3
54.2
46.856.3
27.625.0
33.130.031.3
23.7
38.0
31.3
0
25.0
50.0
75.0
100.0
N
ew
ly
 d
ia
gn
os
ed
 w
ith
ou
t 
tr
ea
tm
en
t 
N
ew
ly
 d
ia
gn
os
ed
 w
ith
 t
re
at
m
en
t 
Pe
rs
is
te
nc
e 
or
 r
ec
ur
re
nc
e
Re
m
is
si
on
N
on
e
Ch
em
ot
he
ra
py
Ra
di
ot
he
ra
py
Co
nc
ur
re
nt
 c
he
m
or
ad
ia
tio
n
10.3
0
12.8
30.025.0
20.310.16.3
51.7
75.0
51.1
30.031.3
54.2
46.856.3
27.625.0
33.130.031.3
23.7
38.0
31.3
N
ew
ly
 d
ia
gn
os
ed
 w
ith
ou
t 
tr
ea
tm
en
t 
N
ew
ly
 d
ia
gn
os
ed
 w
ith
 t
re
at
m
en
t 
Pe
rs
is
te
nc
e 
or
 r
ec
ur
re
nc
e
Re
m
is
si
on
N
on
e
Ch
em
ot
he
ra
py
Ra
di
ot
he
ra
py
Co
nc
ur
re
nt
 c
he
m
or
ad
ia
tio
n
pegIFN-α/RBV treatment. In conclusion, virological and 
biochemical markers (HCV viral load and serum ALT, 
AST, and ALKP levels) were applied in detecting and 
monitoring of HCV disease (Afshar and Mollaie., 2012).
Two of the powerful SVR predictors are virus-related: 
HCV viral load and HCV genotype. Effect of the baseline 
viral load with HCV genotype and IL28B rs12979860 
polymorphism on the treatment response was evaluated. It 
was demonstrated that baseline viral load was significantly 
higher in the patients infected with HCV-1a as compared 
to HCV-3a as well as in non-SVR patients compared with 
SVR patients (p=0.041) (Table 2). Previous reports have 
also confirmed these results (Martinez-Gomez et al., 2012; 
Domagalski et al., 2013). 
In the patients of our study, the overall SVR rate 
was 56% (n=56). SVR rate was 18% in the HCV-1a 
patients and 38% in the HCV-3a patients. A recent work 
demonstrated that there were significantly relashionship 
between HCV genotype and SVR (p=<0.001). A previous 
study on Iranian patients demonstrated that SVR rate in 
HCV-3 was more than that in patients with HCV-1 treated 
with pegIFN-α/RBV (Namazee et al., 2012).
Although an association between baseline viral 
load and IL28B rs12979860 polymorphism has been 
previously described (Ge et al., 2009; Rauch et al., 
2010; Domagalski et al., 2013), in the present study, no 
relationship was observed between viral load and the 
IL28B polymorphisms (p=0.127). 
Frequency of rs12979860 genotypes CC, CT, and TT 
in HCV genotype 1a was 10 (10%), 35 (35%), and 6 (6%), 
respectively and in HCV genotype 3a, it was 13 (13%), 31 
(31%), and 5 (5%), respectively. The results of the present 
study indicate that the IL-28 rs12979860 CT genotype is 
the commonest genotype in CHC patients. These results 
were consistent (Zekri et al., 2014) and inconsistent with 
a number of studies (Sharafi et al., 2012). 
Interestingly, various distributions of IL28B 
rs12979860 genotypes (protective rs12979860 CC 
genotype) among Caucasians, Asians, and Africans 
describe different rates of SVR in these populations. 
Previous studies have confirmed that rs12979860 
CC allele has different frequencies in the worldwide 
population: CC allele’s frequency in African populations 
is 23% to 55%, in European population is 52% to 80%, in 
Southwest Asia is 75% to 98%, and in East Asia is 90% 
to 100% (Thomas et al., 2009).
Alternatively, various SVR rates might be in part 
described by distribution of different rs12979860 alleles 
in different HCV genotypes. In the current study, a lower 
frequency of CC genotype was found in the HCV-1a group 
in comparison with the HCV-3a (Table 3). In addition, it 
was demonstrated that the rs1297860 CC genotype was 
associated with SVR in HCV genotypes 1/3. Relationship 
between IL28B rs12979860 alleles and pegIFN-α/
RBV treatment has been represented in different studies 
(Ge et al., 2009; Suppiah et al., 2009; Balagopal et al., 
2010). The present study showed that CC allele in HCV 
genotype 1 and CC/CT alleles in HCV genotype 3 had an 
important role in infection control and SVR rate in CC 
group was higher than that in TT group among Iranian 
patients with chronic hepatitis C 1/3 (CHC-1/3). Sharafi 
et al. represented that CC and CT alleles in rs12979860, 
responded to treatment better than homozygous TT allele 
(Sharafi et al., 2011). Effect of rs12979860 polymorphism 
on the response to pegIFN-α/RBV treatment in patients 
infected with HCV-1 has been extensively demonstrated. 
Subjects that carry CC allele have SVR rates of more 
than 80%; so, this allele is considered to be favorable. 
By contrast, subjects with TT allele have SVR rates of 
less than 40%; so, it is considered unfavorable. It is clear 
which genotyping of the rs12979860 polymorphism is a 
strong predictor of the clinical outcome for HCV-1 patients 
(Balagopal et al., 2010), but also for HCV-3 to a lesser 
extent (Mangia et al., 2010; Sarrazin et al., 2011). 
SVR rates in CC, CT, and TT (IL28B rs12979860) 
were 18%, 34%, and 4%, respectively. In current study, 
an association was found between SVR rates and IL28B 
polymorphisms. Understanding the associations between 
various IL28B polymorphisms and SVR after treatment 
with pegIFN-α/RBV is a major topic, because there is a 
debate over whether all untreated subjects should get triple 
therapy given the increased costs and possible adverse 
effects. In countries such as Iran, the analysis of offered 
strategies based on IL28B rs129 9860 and SVR could be 
very useful in terms of cost-effectiveness. This analysis 
could also provide benefits related to adverse effects, 
treatment tolerance, a d induction of viral drug resistance 
(Martinez-Gomez et al., 2012). 
In conclusion, the HRM assay described herein was 
rapid, inexpensive, sensitive and accurate for detecting 
rs12979860 alleles in CHC patients. This method can be 
readily adopted by any molecular diagnostic laboratory 
with HRM capability and will be clinically beneficial in 
predicting treatment response in HCV genotype 1 and 3 
infected patients. As also, it was demonstrated that CC 
and CT alleles in HCV-3a and CC allele in HCV-1a were 
significantly associated with response to pegIFN-α/RBV 
treatment. The present results may help identify subjects 
for whom the therapy might be successful.
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